Interim CMO for oncology company
Challenge:
With an unprecedented amount of life science investment being put to work, the industry faces a well known shortage of experienced Chief Medical Officers (CMO). Therefore, following an engagement involving defining clinical strategy for an innovative biopharma company, an experienced Alacrita Partner was deployed as Interim CMO at an innovative biopharma client for over two years.
Solution:
Key activities included:Key activities included:
- Continued development of the lead candidate drug and other therapies in the company’s portfolio
- Medical support for the associated regulatory filings
- Representation of the company to investors and other external parties
Related Case Studies
Explore similar engagements and see how we've helped other clients achieve their goals.
Product Development
Gene therapy preclinical, CMC, and regulatory strategy
Challenge: An early-stage biotechnology startup company reached out to Alacrita for critical support of its two lead AAV-delivered gene therapy programs. As a virtual company, the...
Product Development
Interim chief medical officer for antiviral drug company
Challenge A European company developing novel antiviral drugs urgently needed an experienced pharmaceutical physician to work as an interim CMO, as the predecessor was about to...
Product Development
Preclinical development support for a gene therapy
Challenge: A biotech company developing novel gene therapy approaches for in vivo cell trans-differentiation required an AAV gene therapy expert to serve on a scientific advisory...
Product Development
Primary market research and patient segmentation mapping in myelofibrosis
Challenge: A venture-backed US biotech company was developing a preclinical biologic for haematological indications and wished to quantify the commercial opportunity for the...
Interested in Learning More?
Contact us to discuss how we can support your project with similar expertise.